Cargando…
Second‐line treatments and outcomes for immune thrombocytopenia: A retrospective study with electronic health records
BACKGROUND: Second‐line treatment for immune thrombocytopenia (ITP) is not well reported for patients treated in real‐world clinical settings. OBJECTIVE: The purpose of this study was to compare outcomes of four second‐line treatments for ITP. PATIENTS/METHODS: Included adult patients had at least t...
Autores principales: | Lal, Lincy S., Said, Qayyim, Andrade, Katherine, Cuker, Adam |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7590333/ https://www.ncbi.nlm.nih.gov/pubmed/33134779 http://dx.doi.org/10.1002/rth2.12423 |
Ejemplares similares
-
Eltrombopag treatment of patients with secondary immune thrombocytopenia: retrospective EHR analysis
por: Patwardhan, Pallavi, et al.
Publicado: (2021) -
The clinical and laboratory diagnosis of vaccine-induced immune thrombotic thrombocytopenia
por: Bissola, Anna-Lise, et al.
Publicado: (2022) -
Transitioning patients with immune thrombocytopenia to second‐line therapy: Challenges and best practices
por: Cuker, Adam
Publicado: (2018) -
Tapering thrombopoietin receptor agonists in primary immune thrombocytopenia: Expert consensus based on the RAND/UCLA modified Delphi panel method
por: Cuker, Adam, et al.
Publicado: (2020) -
Natural history of PF4 antibodies in vaccine-induced immune thrombocytopenia and thrombosis
por: Craven, Brian, et al.
Publicado: (2022)